Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514489 | 0.90 | MET (0.60) | METPDGFRBCSF1RFLT3KDR | |
| SCHEMBL4504727 | 0.88 | MET (0.54) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4148024 | 0.81 | CSF1R (0.68) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4560215 | 0.79 | PDGFRB (0.66) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4513314 | 0.77 | PDGFRB (0.65) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4503473 | 0.77 | PDGFRB (0.84) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL2174773 | 0.77 | MET (0.61) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4984789 | 0.77 | PDGFRB (0.52) | METAXLPDGFRBCSF1RFLT3 | |
| SCHEMBL4501657 | 0.77 | KDR (0.64) | METPDGFRBCSF1RFLT3KDR | |
| SCHEMBL4500994 | 0.76 | PDGFRB (0.71) | METAXLPDGFRBCSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | MET 3523/4885AXL 3328/4885PDGFRB 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.